Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

717 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.
Koenig W, Conde LG, Landmesser U, Leiter LA, Ray KK, Schwartz GG, Wright RS, Han J, Raal FJ. Koenig W, et al. Among authors: landmesser u. Cardiovasc Drugs Ther. 2024 Jun;38(3):493-503. doi: 10.1007/s10557-022-07413-0. Epub 2022 Dec 23. Cardiovasc Drugs Ther. 2024. PMID: 36550348 Free PMC article. Clinical Trial.
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, Talloczy Z, Zang X, Maheux P, Lesogor A, Landmesser U. Ray KK, et al. Among authors: landmesser u. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. doi: 10.1016/S2213-8587(22)00353-9. Epub 2023 Jan 5. Lancet Diabetes Endocrinol. 2023. PMID: 36620965 Free article. Clinical Trial.
High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Makhmudova U, Schatz U, Perakakis N, Kassner U, Schumann F, Axthelm C, Stürzebecher P, Sinning DL, Doevelaar A, Rohn B, Westhoff T, Vogt A, Scholl M, Kästner U, Geiling JA, Stach K, Mensch J, Lorenz E, Paitazoglou C, Eitel I, Baessler A, Steinhagen-Thiessen E, Koenig W, Schulze PC, Landmesser U, Laufs U, Weingärtner O; German Inclisiran Network (GIN). Makhmudova U, et al. Among authors: landmesser u. Clin Res Cardiol. 2023 Nov;112(11):1639-1649. doi: 10.1007/s00392-023-02247-8. Epub 2023 Jul 9. Clin Res Cardiol. 2023. PMID: 37422840 Free PMC article.
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention.
Ray KK, Gunn LH, Conde LG, Raal FJ, Wright RS, Gosselin NH, Leiter LA, Koenig W, Schwartz GG, Landmesser U; ORION investigators. Ray KK, et al. Among authors: landmesser u. Atherosclerosis. 2024 Apr;391:117472. doi: 10.1016/j.atherosclerosis.2024.117472. Epub 2024 Feb 15. Atherosclerosis. 2024. PMID: 38447434 Free article. Clinical Trial.
717 results